Global healthcare progresses in step with technological advances, and today there are entirely new algorithms for treating diseases. The COVID-19 pandemic showed that drug security is a top priority, both for the Russian and global economy. Factors such as drug quality certainty, as well as availability and long term continuity of supply (even in emergency situations) are key to national security. The challenges presented by the pandemic have become a powerful stimulus for the development of new mechanisms to ensure drug availability, conduct rapid clinical studies, and develop and manufacture Russian vaccines. For citizens convenience, information technologies and monitoring of drug circulation are being expanded. For a countrys healthcare system and pharma industry to reach a new level of stable growth, ground-breaking technologies are needed. These technologies are also essential to join the international pharmaceutical market, where biomedical cell products are a new driver. What can be done to improve the supply of drugs for preventable diseases, and how can supply deficits be avoided? How can regulation be changed from acting as a barrier to a catalyst for innovation? What steps can be taken so that regulations are harmonized on the EAEU common pharmaceutical market? What approaches to regulating gene therapy and biomedical cell products are required for the industry to grow and for innovative drugs to be created? How can national drug security be ensured? How can Russian citizens be guaranteed continuous availability of high-quality, effective, leading-edge drugs?